Here's Why Shareholders Will Not Be Complaining About J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Pay Packet

Key Insights

• J. B. Chemicals & Pharmaceuticals' Annual General Meeting to take place on 6th of August
• CEO Nikhil Chopra's total compensation includes salary of ₹44.2m
• Total compensation is similar to the industry average
• J. B. Chemicals & Pharmaceuticals' total shareholder return over the past three years was 104% while its EPS grew by 19% over the past three years

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

We have been pretty impressed with the performance at J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) recently and CEO Nikhil Chopra deserves a mention for their role in it. The pleasing results would be something shareholders would keep in mind at the upcoming AGM on 6th of August. The focus will probably be on the future company strategy as shareholders cast their votes on resolutions such as executive remuneration and other matters. We think the CEO has done a pretty decent job and we discuss why the CEO compensation is appropriate.

View our latest analysis for J. B. Chemicals & Pharmaceuticals

How Does Total Compensation For Nikhil Chopra Compare With Other Companies In The Industry?

Our data indicates that J. B. Chemicals & Pharmaceuticals Limited has a market capitalization of ₹278b, and total annual CEO compensation was reported as ₹78m for the year to March 2025. That's a notable increase of 9.0% on last year. We note that the salary of ₹44.2m makes up a sizeable portion of the total compensation received by the CEO.

In comparison with other companies in the Indian Pharmaceuticals industry with market capitalizations ranging from ₹175b to ₹560b, the reported median CEO total compensation was ₹90m. From this we gather that Nikhil Chopra is paid around the median for CEOs in the industry. Moreover, Nikhil Chopra also holds ₹99m worth of J. B. Chemicals & Pharmaceuticals stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

On an industry level, roughly 99% of total compensation represents salary and 0.95087163% is other remuneration. J. B. Chemicals & Pharmaceuticals pays a modest slice of remuneration through salary, as compared to the broader industry. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

A Look at J. B. Chemicals & Pharmaceuticals Limited's Growth Numbers

J. B. Chemicals & Pharmaceuticals Limited has seen its earnings per share (EPS) increase by 19% a year over the past three years. It achieved revenue growth of 12% over the last year.

Shareholders would be glad to know that the company has improved itself over the last few years. It's also good to see decent revenue growth in the last year, suggesting the business is healthy and growing. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.

Has J. B. Chemicals & Pharmaceuticals Limited Been A Good Investment?

We think that the total shareholder return of 104%, over three years, would leave most J. B. Chemicals & Pharmaceuticals Limited shareholders smiling. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

In Summary...

Seeing that the company has put in a relatively good performance, the CEO remuneration policy may not be the focus at the AGM. Instead, investors might be more interested in discussions that would help manage their longer-term growth expectations such as company business strategies and future growth potential.

CEO compensation can have a massive impact on performance, but it's just one element. We've identified 1 warning sign for J. B. Chemicals & Pharmaceuticals that investors should be aware of in a dynamic business environment.

Switching gears from J. B. Chemicals & Pharmaceuticals, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.